Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes
Investigative Opthalmology & Visual Science · 2023
DOI: 10.1167/iovs.64.2.7 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, 2023. Written by Ruiyi Ren and 3 co-authors. Institution: Boston University School of Medicine, Department of Ophthalmology, Boston, Massachusetts, United States. Major MEDLINE topics: Glaucoma, Ocular Hypertension. Cited 20 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NEI NIH HHS.
Abstract (original language)
Purpose
We investigated mechanisms of reduction of intraocular pressure (IOP) by Rho kinase inhibitor AR-12286 in steroid-induced ocular hypertension (SIOH).
Methods
C57BL/6 mice (N = 56) were randomly divided into Saline, dexamethasone (DEX), DEX + AR-12286, and DEX-discontinuation (DEX-DC) groups. IOP was measured weekly during the first four weeks in all groups. Beginning at week 5, the DEX-DC group was followed without treatment until IOP returned to normal, and the other groups were treated as assigned with IOP measured every other day for another week. Fluorescent tracer was injected into the anterior chamber to visualize the outflow pattern in the trabecular meshwork (TM) and TM effective filtration area (EFA) was determined. Radial sections from both high- and low-tracer regions were processed for electron microscopy.
Results
AR-12286 reduced IOP in SIOH mouse eyes in one day (P < 0.01). At the end of week 5, mean IOP in the DEX + AR-12286 group was ∼4 mm Hg lower than DEX group (P < 0.001) and ∼2 mm Hg lower than DEX-DC group (P < 0.05). After one-week AR-12286 treatment (P < 0.05) or five-week DC of DEX (P < 0.01), DEX-induced reduction of EFA was rescued and DEX-induced morphological changes in the TM were partially reversed.
Conclusions
AR-12286 reversed steroid-induced morphological changes in the TM and reduced EFA, which correlated with reduced IOP in SIOH eyes. AR-12286 reduced IOP elevation in SIOH eyes more effectively than discontinuing DEX treatment even when accompanied by continuous DEX treatment. Therefore Rho kinase inhibitors may lower SIOH in patients who rely on steroid treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Boston University School of Medicine, Department of Ophthalmology, Boston, Massachusetts, United States.
- Aerie Pharmaceuticals, Inc., Durham, North Carolina, United States.
Funding
- NEI NIH HHS
Cite
APA
Ren, R., Humphrey, A. A., Kopczynski, C., & Gong, H. (2023). Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.64.2.7
Vancouver
Ren R, Humphrey AA, Kopczynski C, Gong H. Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes. Investigative Opthalmology & Visual Science. 2023. doi:10.1167/iovs.64.2.7
BibTeX
@article{Ren2023,
author = {Ren, Ruiyi and Humphrey, Anne A and Kopczynski, Casey and Gong, Haiyan},
title = {Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
doi = {10.1167/iovs.64.2.7}
}
EUVIMED